DSM is an outsourcing manufacturing partner committed to meeting market demand globally with quality, regulatory excellence and innovations for sustainability. DSM offers preclinical/R&D through Phase I, II and III to commercial scale production for active pharmaceutical ingredients, mammalian cell cultures, microbial fermentation, and, sterile and solid dosage form manufacturing. In Pharma Chemicals, we cover the spectrum from clinical to commercial services to outsource active pharmaceutical ingredients (APIs), registered intermediates (RIs), and registered starting materials.
Suhasini Sharma, Sciformix Corporation ||September 11, 2015 Global biologics market will expand to $250 billion annually by 2020, with biosimilars and non-original biologics commanding 4-10% of that market
Patricia Hurley, Joan Boren and Costantino Congiatu, PPD||June 2, 2015 More than $60 billion worth of patents on biological products are expiring before 2020, representing a major opportunity for the pharmaceutical industry.
Stephanie Mowery, Sherri Rinker, Franklin Spriggs and Bo Kowalcyk , AIT Bioscience||June 2, 2015 Moving forward clinical studies will have to include a comparative assessment of
pharmacokinetics and immunogenicity to the original reference biologic drug
Tjebbe van der Meer, Sartorius Stedim Biotech||June 2, 2015 Continuous improvements in growth media and cell line viability have resulted in increased biomass concentrations in biopharmaceutical production processes, making the downstream purification step more challenging. Body feed filtration has proven to be a successful method of solving similar issues in other industries. This robust technology is now available as a harvesting solution for biotechnology applications.
Walt Berghahn , Healthcare Compliance Packaging Council (HCPC)||June 2, 2015 Spurred by several trends including the patent cliff, new product launches and changes in healthcare, the contract packaging market is looking at sustained growth in the years ahead